Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors
The Phase 1 trial will be a multi-center, open-label, dose escalation and dose expansion study.
- The Phase 1 trial will be a multi-center, open-label, dose escalation and dose expansion study.
- The trial will enroll up to 76 patients with advanced solid tumors whose diseases have failed prior standard therapies.
- While non-ADC therapies are available to treat mCRPC, there is no approved therapy specifically targeting PSMA to treat prostate cancer.
- Ambrx undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.